| Primary |
| Gastrooesophageal Reflux Disease |
33.3% |
| Bladder Disorder |
22.2% |
| Incontinence |
11.1% |
| Neurogenic Bladder |
11.1% |
| Panic Disorder |
11.1% |
| Residual Urine |
11.1% |
|
| Visual Impairment |
22.2% |
| Convulsion |
11.1% |
| Dystonia |
11.1% |
| Medication Error |
11.1% |
| Pharyngeal Oedema |
11.1% |
| Thirst |
11.1% |
| Tremor |
11.1% |
| Vomiting |
11.1% |
|
| Secondary |
| Elevated Mood |
29.3% |
| Drug Use For Unknown Indication |
19.5% |
| Dyspnoea |
17.1% |
| Pain |
14.6% |
| Bipolar Disorder |
2.4% |
| Electrolyte Substitution Therapy |
2.4% |
| Hypertension |
2.4% |
| Impulse-control Disorder |
2.4% |
| Incontinence |
2.4% |
| Neuromyopathy |
2.4% |
| Plasma Cell Myeloma |
2.4% |
| Vitamin Supplementation |
2.4% |
|
| Rash Generalised |
40.0% |
| Anaphylactic Reaction |
10.0% |
| Blood Sodium Increased |
10.0% |
| Nocturia |
10.0% |
| Pain In Extremity |
10.0% |
| Syncope |
10.0% |
| Tracheal Disorder |
10.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
44.6% |
| Drug Use For Unknown Indication |
6.2% |
| Pain |
5.4% |
| Gastrooesophageal Reflux Disease |
4.8% |
| Nausea |
4.6% |
| Hypertension |
4.0% |
| Multiple Sclerosis |
4.0% |
| Colorectal Cancer |
3.6% |
| Diabetes Mellitus |
3.3% |
| Crohn's Disease |
2.1% |
| Muscle Spasms |
2.1% |
| Prophylaxis |
1.9% |
| Gait Disturbance |
1.8% |
| Hypothyroidism |
1.8% |
| Insomnia |
1.8% |
| Osteoporosis |
1.7% |
| Asthma |
1.6% |
| Back Pain |
1.6% |
| Urinary Retention |
1.6% |
| Atrial Fibrillation |
1.5% |
|
| Urinary Tract Infection |
19.2% |
| Weight Increased |
6.7% |
| Pain |
5.8% |
| Renal Impairment |
5.8% |
| Therapeutic Response Decreased |
5.8% |
| Thrombocytopenia |
5.8% |
| Weight Decreased |
5.8% |
| Drug Ineffective |
4.8% |
| Vomiting |
4.8% |
| Death |
3.8% |
| Fall |
3.8% |
| Nausea |
3.8% |
| Tremor |
3.8% |
| Acute Myocardial Infarction |
2.9% |
| Pain In Extremity |
2.9% |
| Renal Failure Acute |
2.9% |
| Sepsis |
2.9% |
| Staphylococcal Infection |
2.9% |
| Swelling |
2.9% |
| Wrong Technique In Drug Usage Process |
2.9% |
|
| Interacting |
|
| Urine Flow Decreased |
100.0% |
|
